Form D · Pharmaceuticals
Andros Medicines Inc.
Boston, MA · CIK 0002138776
Offering snapshot reported Jul 1, 2026 · SEC filing
- Reported sold
- $3.05M Offering amount: $5.05M
- Investors reported
- 2 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 18, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jul 1, 2026 | Initial | $3,049,999 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-589259
Source: Form D, filed Jul 1, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Antoine Barouky | Director |
| Khalil Barrage | Director |
| John Maraganore | Director, Executive |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
1 Franklin Street, #Ph2 B
Boston, MA, 02110
Boston, MA, 02110